Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
BNOX | US
-0.00
-1.53%
Healthcare
Biotechnology
30/06/2024
21/10/2024
0.30
0.32
0.32
0.28
Bionomics Limited a clinical stage biopharmaceutical company discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210 a negative allosteric modulator of the a7 nicotinic acetylcholine receptor which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101 a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105 which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited was incorporated in 1996 and is based in Eastwood Australia.
View LessLow Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Operating Margin (> 25%)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
77.0%1 month
145.5%3 months
119.3%6 months
113.1%-
-
0.27
0.01
0.00
-0.06
62.94
-
-17.35M
5.12M
5.12M
-
8.91K
-
9.30
-78.44
0.46
0.67
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.09
Range1M
0.44
Range3M
0.71
Rel. volume
0.42
Price X volume
39.19K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
PALISADE BIO INC | PALI | Biotechnology | 3.91 | 5.41M | 0.51% | n/a | 5.06% |
ERNA | ERNA | Biotechnology | 0.9899 | 5.36M | -2.95% | n/a | -577.12% |
XORTX Therapeutics Inc. Common Stock | XRTX | Biotechnology | 1.71 | 5.15M | -9.04% | n/a | 3.09% |
180 Life Sciences Corp | ATNF | Biotechnology | 4.97 | 5.10M | -1.19% | n/a | -105.81% |
Molecular Templates Inc | MTEM | Biotechnology | 0.75 | 4.94M | 0.00% | n/a | 155.07% |
QLGN | QLGN | Biotechnology | 0.1825 | 4.93M | 9.15% | n/a | -39.04% |
Enveric Biosciences Inc | ENVB | Biotechnology | 0.538 | 4.80M | 20.33% | n/a | 0.00% |
CNS PHARMACEUTICALS INC | CNSP | Biotechnology | 0.146 | 4.69M | 19.67% | n/a | -2.87% |
Azitra Inc | AZTR | Biotechnology | 0.61 | 4.65M | 0.00% | 0.01 | 41.86% |
ADTX | ADTX | Biotechnology | 1.09 | 4.60M | 3.81% | n/a | 122.46% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.4659 | 4.44M | -2.96% | n/a | 19.98% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.19 | 2.99M | -13.68% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.06 | 2.71M | 0.00% | n/a | 17.32% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.65 | 2.01M | -6.89% | n/a | 0.00% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.011 | 1.01M | 10.00% | n/a | -37.05% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -0.06 | 0.53 | Cheaper |
Ent. to Revenue | 62.94 | 3,967.00 | Cheaper |
PE Ratio | - | 41.03 | - |
Price to Book | 0.27 | 15.55 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 119.32 | 72.80 | Riskier |
Debt to Equity | 0.01 | -1.23 | Expensive |
Debt to Assets | 0.00 | 0.25 | Cheaper |
Market Cap | 5.12M | 3.66B | Emerging |